# D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC

> **NCT06643208** · — · RECRUITING · sponsor: **Fujian Provincial Hospital** · enrollment: 37 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **DRUG:** TACE-HAIC, Envafolimab and Lenvatinib

## Key facts

- **NCT ID:** NCT06643208
- **Lead sponsor:** Fujian Provincial Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06643208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06643208, "D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06643208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*